我們已在上線！進一步了解

VolitionRx Ltd

VNRX

市值 US$541萬

0.1801 USD

-0.0084

4.46%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.1801

0.0000

0%

1天

-4.46%

5天

-16.62%

1個月

-34.49%

3個月

-84.47%

6個月

-94.88%

今年迄今

-96.7%

1年

-97.99%

5年

-99.74%

10年

-99.82%

關於： VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

員工： 75

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 7.7%

中性 92.3%

負面 0%

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX ) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

VolitionRx Participates in Launch of DETECSEPS Program in France

French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces, as part of the DETECSEPS Consortium, the official launch of the DETECSEPS project on the early detection of sepsis.

VolitionRx Participates in Launch of DETECSEPS Program in France

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind").

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Nev.

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

查看新聞排名

價格圖表採用Lightweight Charts™實作